Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research

Neuropsychobiology

Volumn 42, Issue 1, 2000, Pages 34-41

  Curran, H Valerie ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cognitive function; Ecstasy; Evidence; MDMA; Memory; Methods; Mood; Neurobiology; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ARTICLE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL RESEARCH; METHODOLOGY; NEUROBIOLOGY; NEUROENDOCRINOLOGY; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOSOMATICS;

EID: 0033921324     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026668     Document Type: Article

References (31)

1. Schmidt CJ: Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987:240:1-7.
2. Rudnick G, Wall SC: The molecular mechanism of 'ecstasy' [3,4-methylenedioxymethamphelamine (MDMA)]: Scrotonin transporters are targets for MDMA-induced scrotonin release. Proe Nat Acad Sci USA 1992;89:1817-1821.
3. Green AR, Cross AJ, Goodwill GM: Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology. 1995;119:247-260.
4. Ricaurte GA, DeLanney L, Irwin I, Langston JW: Toxic effects of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of administration. Brain Res 1988;446:165-168.
5. Insel TR, Battaglia G, Johannessen JN, Marra S. DeSouza EB: 3,4-Methylenedioxymethamphetamine ('ecstasy') selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 1989;249:713-720.
6. Sprague JE, Everman SL, Nichols DE: An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 1988:19:427-441.
7. Smith KA, Fairburn CG,Cowen PJ: Relapse of depression after rapid tryptophan depletion. Lancet 1997;49:915-919.
8. Park SB, Coull JT, MeShane RH, Young AH, Sahakian BJ, Robbins TW, Cowen PJ: Tryptophan depletion in normal volunteers produces selective impairments of learning and memory. Neuropharmacology 1994;33:575-588.
9. McCann, UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA: Positron emission tomographic evidence of toxic effects of MDMA ('ecstasy') on brain serotonin neurons in human beings. Lancet 1998;352:1433-1437.
10. Simuntov R, Tauber M: The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells. FASEB 1997;11: 141-146.
11. Ricaurte GA, Finnegan KT, Irwin I, Langston JW: Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: Preliminary observations, Ann N Y Acad Sci 1990;600:699-710.
12. McCann UD, Ridenour A, Shaham Y, Ricaurte GA: Serotonin neurotoxicity after MDMA: A controlled study in humans. Neuropsychopharmacology 1994;10:129-138.
13. Gerra G, Zaimovic A, Guicastro G, Maestri D, Monica, C. Sartori R. Caccavari R, Delsignore R: Scrotonergic function after ± 3,4-methylene-dioxymethamphetamine ('Ecstasy') in humans. Int Clin Psychopharmacol 1998;13:1-9.
14. McCann UD, Ricaurtc GA: Reinforcing subjective effects of ± 3,4-methylenedioxymethamphetamine ('ecstasy') may be separable from its neurotoxic actions: Clinical evidence. J Clin Psychopharmacol 1993;3:214-217.
15. Greer G. Tolbert P: Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18:319-327.
16. Downing J: The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986;18:335-340.
17. Vollenweider FX, Gamma A, Liechti M, Huber T: Psychological and cardiovascular effects and short-term sequelae of MDMA ('Ecstasy') in humans. Neuropsychopharmacology 1998; 19:241-249.
18. Licster MB, Grob CS, Bravo GL, Walsh RN: Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 1992;180:345-352.
19. Parrott AC, Lasky J: Ecstasy (MDMA) effects upon mood and cognition: Before, during and after a Saturday night dance. Psychopharmacology 1998;139:261-268.
20. Curran HV, Travill RA: Mood and cognitive effects of ± 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): Weekend high followed by mid-week low. Addiction 1997;92: 821-831.
21. Petrouka SJ, Newman H, Harris H: Subjective effects of 3,4-methylenedioxymethamphetaminein recreational users. Neuropsychopharmacology 1988; 1:273-277.
22. Cohen RS: Subjective reports of the effects of the MDMA (Ecstasy) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1137-1145.
23. Allen RP, MeCann UD, Ricaurte GA: Persistent effects of ± 3,4-methylenedioxymethamphetamine on human sleep. Sleep 1993;16: 560-564.
24. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR: Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 1992;18:331-341.
25. Parrot AC, Lees A, Garnham NJ, Jones M, Wesnes K: Cognitive performance in recreational users of MDMA or 'ecstasy': Evidence for memory deficits. J Psychopharmacol 1998; 12:79-83.
26. Morgan MJ: Memory deficits associated with recreational use of 'ecstasy' (MDMA). Psychopharmacology 1999;141:30-36.
27. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R: MDMA ('ecstasy') consumption in the content of polydrug abuse: A report on 150 patients. Drug Alcohol Depend 1998;52:85-90.
28. Cohen RS, Cocores J: Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA: 'ecstasy'). Prog Neuropsychopharmacol Biol Psychiatry 1997;21:727-734.
29. McCann UD, Ricaurte G: MDMA (Ecstasy) and panic disorder: Induction by a single dose. Biol Psychiatry 1992;32:950-953.
30. McGuirE PK, Cope H, Fahy TA: Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('ecstasy'). Br J Psychiatry 1994;165:391-395.
31. Merrill J: Ecstasy and neurodegeneration: Advice is that 'less is more'. Br Med J 1996;313: 423.